About Us
Engage with the leading edge of biopharmaceuticals

History

The Bexion Story

2016

Bexion Pharmaceuticals Receives FDA Clearance for the First Clinical Trial Using BXQ-350 to Dose Patients with Cancer

2015

Bexion Pharmaceuticals Receives Orphan Drug Designation for Saposin C, the Active Ingredient in BXQ-350 for Glioblastoma Multiforme from FDA. Bexion wins a Tibbett's Award by the Small Business Administration for exemplifying the very best in innovation.

2014

Bexion prepares IND for Phase 1

2013

Bexion wins prestigious $2.9MM NCI Bridge Award for Phase 1 in brain cancer

2012

BXQ-350 in IND-enabling studies in preparation for Phase 1 clinical studies

2011

Bexion held a very successful Pre-IND meeting with the FDA. Bexion plans to complete pre-tox animal studies and file IND with the FDA

FDA

2010

Bexion wins partnership with Nanotechnology Characterization Lab of NCI, and also $1.5MM NIH grant for brain cancer.

Nanotechnology Characterization Lab

2009

Bexion wins grants to study brain, pancreatic and prostate cancer.

National Cancer Institue

Bexion obtains Series A investment to fund efforts up to Phase 1 clinical study.

2006

Ray Takigiku, Ph.D. co-founds Bexion Pharmaceuticals; licenses anti-cancer technology from CCHMC

Dr. Ray Takigiku, Ph.D.

2004

Dr. Qi receives a small grant to study the protein on childhood cancer.

CancerFree Kids

2002

Dr. Qi discovers that a protein involved in the inherited disease has anti-cancer properties.

Xiaoyang Qi, Ph.D.

1996

Xiaoyang Qi, Ph.D., a geneticist, joins CCHMC to find a cure for a rare inherited disease.

CCHMC
About Us